Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Gauthier

Showing results (111-120 of 135) with videos related to

Pageof 14
Sort By:
Journal of Medicinal Chemistry|October 1, 1990
Stereospecific synthesis, assignment of absolute configuration, and biological activity of the enantiomers of 3-[[[3-[2-(7-chloroquinolin-2-yl)-(E)-ethenyl]phenyl] [[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]propionic acid, a potent and specific leukotriene D4 receptor antagonistJ Y Gauthier, T Jones, E Champion, et al.
The British Journal of Dermatology|March 18, 2011
Multivariate analysis of factors associated with early-onset segmental and nonsegmental vitiligo: a prospective observational study of 213 patientsK Ezzedine, A Diallo, C Léauté-Labrèze, et al.
The British Journal of Dermatology|October 29, 2011
Halo naevi and leukotrichia are strong predictors of the passage to mixed vitiligo in a subgroup of segmental vitiligoK Ezzedine, A Diallo, C Léauté-Labrèze, et al.
Canadian Journal of Physiology and Pharmacology|February 1, 1995
Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonistT R Jones, M Labelle, M Belley, et al.
Molecular Pharmacology|July 1, 1991
5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitorsJ F Evans, C Lévillé, J A Mancini, et al.
Canadian Journal of Physiology and Pharmacology|December 1, 1991
Pharmacology of the leukotriene antagonist verlukast: the (R)-enantiomer of MK-571T R Jones, R Zamboni, M Belley, et al.
Canadian Journal of Physiology and Pharmacology|January 1, 1989
Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonistT R Jones, R Zamboni, M Belley, et al.
Canadian Journal of Physiology and Pharmacology|August 1, 1986
L-649,923, sodium (beta S*, gamma R*)-4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propylthio)- gamma-hydroxy-beta-methylbenzenebutanoate, a selective, orally active leukotriene receptor antagonistT R Jones, R Young, E Champion, et al.
Journal of Medicinal Chemistry|September 1, 1986
Design and synthesis of sodium (beta R*, gamma S*)-4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl] thio]-gamma-hydroxy-beta-methylbenzenebutanoate: a novel, selective, and orally active receptor antagonist of leukotriene D4R N Young, P Bélanger, E Champion, et al.
The British Journal of Dermatology|September 27, 2014
Hypochromic vitiligo: delineation of a new entityK Ezzedine, A Mahé, N van Geel, et al.
Pageof 14

Showing results (111-120 of 135) with videos related to

Sort By:
Pageof 14
Journal of Medicinal Chemistry|October 1, 1990
Stereospecific synthesis, assignment of absolute configuration, and biological activity of the enantiomers of 3-[[[3-[2-(7-chloroquinolin-2-yl)-(E)-ethenyl]phenyl] [[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]propionic acid, a potent and specific leukotriene D4 receptor antagonistJ Y Gauthier, T Jones, E Champion, et al.
The British Journal of Dermatology|March 18, 2011
Multivariate analysis of factors associated with early-onset segmental and nonsegmental vitiligo: a prospective observational study of 213 patientsK Ezzedine, A Diallo, C Léauté-Labrèze, et al.
The British Journal of Dermatology|October 29, 2011
Halo naevi and leukotrichia are strong predictors of the passage to mixed vitiligo in a subgroup of segmental vitiligoK Ezzedine, A Diallo, C Léauté-Labrèze, et al.
Canadian Journal of Physiology and Pharmacology|February 1, 1995
Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonistT R Jones, M Labelle, M Belley, et al.
Molecular Pharmacology|July 1, 1991
5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitorsJ F Evans, C Lévillé, J A Mancini, et al.
Canadian Journal of Physiology and Pharmacology|December 1, 1991
Pharmacology of the leukotriene antagonist verlukast: the (R)-enantiomer of MK-571T R Jones, R Zamboni, M Belley, et al.
Canadian Journal of Physiology and Pharmacology|January 1, 1989
Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonistT R Jones, R Zamboni, M Belley, et al.
Canadian Journal of Physiology and Pharmacology|August 1, 1986
L-649,923, sodium (beta S*, gamma R*)-4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propylthio)- gamma-hydroxy-beta-methylbenzenebutanoate, a selective, orally active leukotriene receptor antagonistT R Jones, R Young, E Champion, et al.
Journal of Medicinal Chemistry|September 1, 1986
Design and synthesis of sodium (beta R*, gamma S*)-4-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl] thio]-gamma-hydroxy-beta-methylbenzenebutanoate: a novel, selective, and orally active receptor antagonist of leukotriene D4R N Young, P Bélanger, E Champion, et al.
The British Journal of Dermatology|September 27, 2014
Hypochromic vitiligo: delineation of a new entityK Ezzedine, A Mahé, N van Geel, et al.
Pageof 14